These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 29407294

  • 1. Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.
    Nanmoku K, Shinzato T, Kubo T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2018; 50(1):124-129. PubMed ID: 29407294
    [Abstract] [Full Text] [Related]

  • 2. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Halleck F, Khadzhynov D, Schrezenmeier E, Lehner L, Budde K, Staeck O.
    Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
    [Abstract] [Full Text] [Related]

  • 3. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 4. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr 27; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 5. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.
    Transplant Proc; 2007 Sep 27; 39(7):2228-30. PubMed ID: 17889146
    [Abstract] [Full Text] [Related]

  • 6. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I.
    J Med Virol; 2013 May 27; 85(5):893-8. PubMed ID: 23508914
    [Abstract] [Full Text] [Related]

  • 7. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S, Li C, Cross RP, DePiero KA, Dick TB, Ferguson K, Kim M, Newkirk E, Park JM, Sudaria-Kerr J, Tichy EM, Ueda KR, Weng R, Wisniewski J, Gabardi S.
    Transpl Infect Dis; 2016 Dec 27; 18(6):904-912. PubMed ID: 27639246
    [Abstract] [Full Text] [Related]

  • 8. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 9. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD.
    Am J Kidney Dis; 2002 May 15; 39(5):1088-95. PubMed ID: 11979354
    [Abstract] [Full Text] [Related]

  • 10. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease.
    Fayek SA, Beshears E, Lieber R, Alvey N, Sauer A, Poirier J, Hollinger EF, Olaitan OK, Jensik S, Geyston J, Brokhof MM, Hodowanec AC, Hertl M, Simon DM.
    Transplant Proc; 2016 May 15; 48(6):2056-2064.e1. PubMed ID: 27569944
    [Abstract] [Full Text] [Related]

  • 11. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 May 15; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 12. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S.
    Transplantation; 2010 Nov 27; 90(10):1091-8. PubMed ID: 20885340
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S, Asipenko N, Fleming J, Lor K, McDevitt-Potter L, Mohammed A, Rogers C, Tichy EM, Weng R, Lee RA.
    Transplantation; 2015 Jul 27; 99(7):1499-505. PubMed ID: 25643140
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
    Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK.
    Pharmacotherapy; 2004 Oct 27; 24(10):1323-30. PubMed ID: 15628830
    [Abstract] [Full Text] [Related]

  • 15. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.
    Lapidus-Krol E, Shapiro R, Amir J, Davidovits M, Steinberg R, Mor E, Avitzur Y.
    Pediatr Transplant; 2010 Sep 01; 14(6):753-60. PubMed ID: 20477976
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 17. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.
    Transplant Proc; 2005 Sep 16; 37(7):3182-6. PubMed ID: 16213344
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan 16; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

  • 19. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
    Weng FL, Patel AM, Wanchoo R, Brahmbhatt Y, Ribeiro K, Uknis ME, Mulgaonkar S, Mathis AS.
    Transplantation; 2007 Feb 15; 83(3):290-6. PubMed ID: 17297403
    [Abstract] [Full Text] [Related]

  • 20. Low-dose valganciclovir prophylaxis for cytomegalovirus in intermediate-risk (R+) renal transplant recipients: Single-center experience.
    Khan S, Fischman C, Huprikar S.
    Transpl Infect Dis; 2017 Dec 15; 19(6):. PubMed ID: 28940831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.